Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

Raghav, Kanwal Pratap Singh;Siena, Salvatore;Takashima, Atsuo;Kato, Takeshi;Yoshino, Takayuki;et.al.
(2023) American Society of ClinicalOncology (ASCO)2023 — Location: McCormick Place, 2301 S King Dr, Chicago, IL 60616, USA (2.June.2023)

Files

jco20234116_suppl3501.pdf
  • Open Access
  • Adobe PDF
  • 42.32 KB
Download

Details

Authors
  • Raghav, Kanwal Pratap Singh
    Author
  • Siena, Salvatore
    Author
  • Takashima, Atsuo
    Author
  • Kato, Takeshi
    Author
  • Van den Eynde, MarcUCLouvain
    Author
  • Yoshino, Takayuki
    Author
Show more
Abstract
Background: T-DXd (6.4 mg/kg, every 3 weeks [Q3W]) demonstrated antitumor activity in pts with HER2+ mCRC in DESTINY-CRC01 (Siena et al. Lancet Oncol. 2021). We present primary results of DESTINY-CRC02 (NCT04744831), which assessed the efficacy and safety of T-DXd (5.4 and 6.4 mg/ kg) in pts with HER2+ mCRC. Methods: This was a multicenter phase 2 study. Eligible pts had centrally confirmed HER2+ (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) mCRC. Pts with RAS wild-type (wt) or mutant (m) mCRC were eligible. Pts had received prior standard therapy, unless contraindicated; prior anti-HER2 therapy was allowed. In stage 1, 80 pts were randomized 1:1 to 5.4 (n = 40) or 6.4 (n = 40) mg/kg T-DXd Q3W. In stage 2, an additional 42 pts received 5.4 mg/kg TDXd. Primary endpoint was confirmed objective response rate (cORR) by blinded independent central review (BICR). Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Results: At data cutoff (Nov 1, 2022), most pts in the 5.4 and 6.4 mg/kg T-DXd arms had HER2 IHC 3+ (78.0% and 85.0%), RAS wt tumors (82.9% and 85.0%), and a median of 3 and 4 prior lines of therapy, respectively. cORR was 37.8% (95% CI, 27.3-49.2%) in the 5.4 mg/kg arm and 27.5% (95% CI, 14.6-43.9%) in the 6.4 mg/kg arm (all partial responses in both arms). Key efficacy data are shown in the Table: Grade $3 treatment-emergent adverse events (AEs) were observed in 41/83 pts (49.4%) and 23/39 pts (59.0%) in the 5.4 and 6.4 mg/kg T-DXd arms, respectively. Serious AEs were observed in 20/83 pts (24.1%) and 12/39 pts (30.8%) in the 5.4 and 6.4 mg/kg arms, respectively. Independently adjudicated drug-related interstitial lung disease occurred in 7/83 pts (8.4%) with 5.4 mg/kg T-DXd and 5/39 pts (12.8%) with 6.4 mg/kg T-DXd, and most events were grade 1/2 (1 grade 5 in the 6.4 mg/kg arm). Conclusions: T-DXd showed promising antitumor activity in pts with HER2+ mCRC at both 5.4 and 6.4 mg/kg doses. Antitumor efficacy was observed irrespective of RAS mutation status at 5.4 mg/kg T-DXd, and in those with prior anti-HER2 therapy. Overall, safety was consistent with the known safety profile of T-DXd and favored the 5.4 mg/kg dose. Clinical trial information: NCT04744831
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Raghav, K. P. S., Siena, S., Takashima, A., Kato, T., Van den Eynde, M., Di Bartolomeo, M., Komatsu, Y., Kawakami, H., Peeters, M., Andre, T., Lonardi, S., Yamaguchi, K., Tie, J., Gravalos Castro, C., Strickler, J. H., Barrios, D., Yan, Q., Kamio, T., Kobayashi, K., & Yoshino, T. (2023). Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. Journal of Clinical Oncology, 41(16_suppl), 3501. https://doi.org/10.1200/jco.2023.41.16_suppl.3501 (Original work published 2023)